Santaris Pharma Raises EUR 20 Million of New Equity

Santaris Pharma A/S has completed a new EUR 20 million private investment round. Gilde Healthcare Partners, a new investor in the Company, contributed EUR 7.5 million of the financing, with the remaining EUR 12.9 million provided by a strong international syndicate of existing investors, including BankInvest, Novo, LD, Forbion Capital Partners, Global Life Science Venture, Sunstone Capital, Seventure, Omega, Innovation Capital and members of the Company's board and management.

The proceeds of the financing will be used primarily to fund continued development of Santaris Pharma's pipeline of innovative RNA antagonist drug candidates based on its breakthrough LNA chemistry. The Company expects to advance its SPC2996 compound, an RNA Antagonist of Bcl-2, into Phase II clinical trials in Chronic Lymphocytic Leukaemia and B-cell Lymphoma and to initiate phase I volunteer studies of two new RNA antagonists for the treatment of metabolic disorders.

Edwin de Graaf, General Partner of Gilde Healthcare Partners, said: "We invest in biopharmaceutical companies with strong technology platforms and experienced management and we have a strong portfolio of international companies. Santaris Pharma is well positioned to become a leader in the field of RNA medicines. It is a company that quickly has built an impressing and promising pipeline of drug candidates, which are getting ready to be validated in the clinic."

For further information please contact:

Randi Krogsgaard,

Director of Corporate Communications

Tel: +45 45 17 98 79

E-mail: rmk@santaris.com